|
1
|
Liu H, Wang Y, Zhang Y, et al: TFAR19, a
novel apoptosis-related gene cloned from human leukemia cell line
TF-1, could enhance apoptosis of some tumor cells induced by growth
factor withdrawal. Biochem Biophys Res Commun. 254:203–210. 1999.
View Article : Google Scholar
|
|
2
|
Xu L, Chen Y, Song Q, Xu D, Wang Y and Ma
D: PDCD5 interacts with Tip60 and functions as a cooperator in
acetyltransferase activity and DNA damage-induced apoptosis.
Neoplasia. 11:345–354. 2009.PubMed/NCBI
|
|
3
|
Salvi M, Xu D, Chen Y, Cabrelle A, Sarno S
and Pinna LA: Programmed cell death protein 5 (PDCD5) is
phosphorylated by CK2 in vitro and in 293T cells. Biochem Biophys
Res Commun. 387:606–610. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rui M, Chen Y, Zhang Y and Ma D: Transfer
of anti-TFAR19 monoclonal antibody into HeLa cells by in situ
electroporation can inhibit the apoptosis. Life Sci. 71:1771–1778.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Han XR, Sun Y and Bai XZ: The anti-tumor
role and mechanism of integrated and truncated PDCD5 proteins in
osteosarcoma cells. Cell Signal. 24:1713–1721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang X, Wang X, Song X, et al: Clinical
and prognostic significance of lost or decreased PDCD5 expression
in human epithelial ovarian carcinomas. Oncol Rep. 25:353–358.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li H, Wang Q, Gao F, et al: Reduced
expression of PDCD5 is associated with high-grade astrocytic
gliomas. Oncol Rep. 20:573–579. 2008.PubMed/NCBI
|
|
8
|
Chen C, Zhou H, Xu L, et al: Prognostic
significance of downregulated expression of programmed cell death 5
in chondrosarcoma. J Surg Oncol. 102:838–843. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yin A, Jiang Y, Zhang X, Zhao J and Luo H:
Transfection of PDCD5 sensitizes colorectal cancer cells to
cisplatin-induced apoptosis in vitro and in vivo. Eur J Pharmacol.
649:120–126. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bao L, Ruan GR, Lu XJ, et al: Abnormal
expression of programmed cell death 5 gene in multiple myeloma
patients. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 18:634–637. 2010.(In
Chinese).
|
|
11
|
Du YJ, Xiong L, Lou Y, Tan WL and Zheng
SB: Reduced expression of programmed cell death 5 protein in tissue
of human prostate cancer. Chin Med Sci J. 24:241–245. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ruan GR, Chen SS, Ma X, et al: Abnormal
expression of PDCD5 in the bone marrow cells of adult acute myeloid
leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 15:462–465. 2007.(In
Chinese).
|
|
13
|
Tan WL, Xiong L, Zheng SB, et al:
Relationship between programmed cell death 5 protein expression and
prognosis of renal clear cell carcinoma. Nan Fang Yi Ke Da Xue Xue
Bao. 26:1316–1318. 2006.(In Chinese).
|
|
14
|
Xiong L, Tan WL, Yu ZC, et al: Expression
of TFAR19 (PDCD5) in normal human kidney, renal clear cell
carcinoma, normal human bladder and bladder carcinoma. Nan Fang Yi
Ke Da Xue Xue Bao. 26:805–809. 2006.(In Chinese).
|
|
15
|
Spinola M, Meyer P, Kammerer S, et al:
Association of the PDCD5 locus with lung cancer risk and prognosis
in smokers. J Clin Oncol. 24:1672–1678. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang YH, Zhao M, Li WM, et al: Expression
of programmed cell death 5 gene involves in regulation of apoptosis
in gastric tumor cells. Apoptosis. 11:993–1001. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Paral J, Slaninka I, Kalabova H and
Hadzi-Nikolov D: Gastrointestinal stromal tumors: review on
morphology, molecular pathology, diagnostics, prognosis and
treatment options. Acta Gastroenterol Belg. 73:349–359. 2010.
|
|
18
|
Lai Eric CH, Lau Stephanie HY and Lau WY:
Current management of gastrointestinal stromal tumors - a
comprehensive review. Int J Surg. 10:334–340. 2012.PubMed/NCBI
|
|
19
|
Bayraktar UD, Bayraktar S and Rocha-Lima
CM: Molecular basis and management of gastrointestinal stromal
tumors. World J Gastroenterol. 16:2726–2734. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liegl-Atzwanger B, Fletcher JA and
Fletcher CD: Gastrointestinal stromal tumors. Virchows Arch.
456:111–127. 2010. View Article : Google Scholar
|
|
21
|
Fletcher CD, Berman JJ, Corless C, et al:
Diagnosis of gastrointestinal stromal tumors: a consensus approach.
Int J Surg Pathol. 10:81–89. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chadderton T, Wilson C, Bewick M and Gluck
S: Evaluation of three rapid RNA extraction reagents: relevance for
use in RT-PCR’s and measurement of low level gene expression in
clinical samples. Cell Mol Biol. 43:1227–1234. 1997.PubMed/NCBI
|
|
23
|
Culley DE, Kovacik WP Jr, Brockman FJ and
Zhang W: Optimization of RNA isolation from the archaebacterium
Methanosarcina barkeri and validation for oligonucleotide
microarray analysis. J Microbiol Methods. 67:36–43. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Laurini JA and Carter JE: Gastrointestinal
stromal tumors: a review of the literature. Arch Pathol Lab Med.
134:134–141. 2010.
|
|
25
|
Xu HY, Chen ZW, Pan YM, et al:
Transfection of PDCD5 effect on the biological behavior of tumor
cells and sensitized gastric cancer cells to cisplatin-induced
apoptosis. Dig Dis Sci. 57:1847–1856. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang Y, Chu H, Zhou L, et al: Correlation
of PDCD5 and apoptosis in hair cells and spiral ganglion neurons of
different age of C57BL/6J mice. J Huazhong Univ Sci Technolog Med
Sci. 32:113–118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ruan GR, Zhao HS, Chang Y, et al:
Adenovirus-mediated PDCD5 gene transfer sensitizes K562 cells to
apoptosis induced by idarubicin in vitro and in vivo. Apoptosis.
13:641–648. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang YF, Song QS, Zhang YM, Ma DL, Wang Y
and Ke XY: Sensitizing effect of recombinant human PDCD5 protein on
chemotherapy of acute monocytic leukemia cell line U937 and its
mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 18:277–281. 2010.(In
Chinese).
|
|
29
|
de Matteo RP, Ballman KV, Antonescu CR, et
al: Adjuvant imatinib mesylate after resection of localised,
primary gastrointestinal stromal tumour: a randomised,
double-blind, placebo-controlled trial. Lancet. 373:1097–1104.
2009.
|
|
30
|
Gramza AW, Corless CL and Heinrich MC:
Resistance to tyrosine kinase inhibitors in gastrointestinal
stromal tumors. Clin Cancer Res. 15:7510–7518. 2009. View Article : Google Scholar : PubMed/NCBI
|
